INTRODUCTION: Sickle cell disease (SCD)-associated vasculopathy in the penis is characterized by aberrant nitric oxide and phosphodiesterase (PDE) 5 signaling, and by increased oxidative stress. Preliminary clinical trials show that continuous treatment with PDE5 inhibitor sildenafil unassociated with sexual activity decreases priapic activity in patients with SCD. However, the mechanism of its vasculoprotective effect in the penis remains unclear. AIMS: We evaluated whether continuous administration of PDE5 inhibitor sildenafil promotes eNOS function at posttranslational levels and decreases superoxide-producing enzyme NADPH oxidase activity in the sickle cell mouse penis. METHODS: SCD transgenic mice were used as an animal model of SCD. WT mice served as controls. Mice received treatment with the PDE5 inhibitor sildenafil (100 mg/kg/day) or vehicle for 3 weeks. eNOS phosphorylation on Ser-1177 (positive regulatory site), eNOS interactions with heat-shock protein 90 (HSP90) (positive regulator), phosphorylated AKT (upstream mediator of eNOS phosphorylation on Ser-1177), an NADPH oxidase catalytic subunit gp91(phox), and a marker of oxidative stress (4-hydroxy-2-nonenal [HNE]) were measured by Western blot. MAIN OUTCOME MEASURES: Effect of continuous sildenafil treatment on eNOS posttranslational activation, NADPH oxidase catalytic subunit, and oxidative stress in the penis of the sickle cell mouse. RESULTS: Continuous treatment with sildenafil reversed (P < 0.05) the abnormalities in protein expressions of P-eNOS (Ser-1177), eNOS/HSP90 interaction, P-AKT, protein expression of gp91(phox), and 4-HNE, in the sickle cell mouse penis. Sildenafil treatment of WT mice did not affect any of these parameters. CONCLUSION: Our findings that sildenafil enhances eNOS activation and inhibits NADPH oxidase function in the sickle cell mouse penis offers a vasculoprotective molecular basis for the therapeutic effect of sildenafil in the penis in association with SCD.
INTRODUCTION:Sickle cell disease (SCD)-associated vasculopathy in the penis is characterized by aberrant nitric oxide and phosphodiesterase (PDE) 5 signaling, and by increased oxidative stress. Preliminary clinical trials show that continuous treatment with PDE5 inhibitor sildenafil unassociated with sexual activity decreases priapic activity in patients with SCD. However, the mechanism of its vasculoprotective effect in the penis remains unclear. AIMS: We evaluated whether continuous administration of PDE5 inhibitor sildenafil promotes eNOS function at posttranslational levels and decreases superoxide-producing enzyme NADPH oxidase activity in the sickle cell mouse penis. METHODS:SCDtransgenic mice were used as an animal model of SCD. WT mice served as controls. Mice received treatment with the PDE5 inhibitor sildenafil (100 mg/kg/day) or vehicle for 3 weeks. eNOS phosphorylation on Ser-1177 (positive regulatory site), eNOS interactions with heat-shock protein 90 (HSP90) (positive regulator), phosphorylated AKT (upstream mediator of eNOS phosphorylation on Ser-1177), an NADPH oxidase catalytic subunit gp91(phox), and a marker of oxidative stress (4-hydroxy-2-nonenal [HNE]) were measured by Western blot. MAIN OUTCOME MEASURES: Effect of continuous sildenafil treatment on eNOS posttranslational activation, NADPH oxidase catalytic subunit, and oxidative stress in the penis of the sickle cell mouse. RESULTS: Continuous treatment with sildenafil reversed (P < 0.05) the abnormalities in protein expressions of P-eNOS (Ser-1177), eNOS/HSP90 interaction, P-AKT, protein expression of gp91(phox), and 4-HNE, in the sickle cell mouse penis. Sildenafil treatment of WT mice did not affect any of these parameters. CONCLUSION: Our findings that sildenafil enhances eNOS activation and inhibits NADPH oxidase function in the sickle cell mouse penis offers a vasculoprotective molecular basis for the therapeutic effect of sildenafil in the penis in association with SCD.
Authors: K Joseph Hurt; Biljana Musicki; Michael A Palese; Julie K Crone; Robyn E Becker; John L Moriarity; Solomon H Snyder; Arthur L Burnett Journal: Proc Natl Acad Sci U S A Date: 2002-03-19 Impact factor: 11.205
Authors: Hunter C Champion; Trinity J Bivalacqua; Eiki Takimoto; David A Kass; Arthur L Burnett Journal: Proc Natl Acad Sci U S A Date: 2005-01-24 Impact factor: 11.205
Authors: Biljana Musicki; Hunter C Champion; Robyn E Becker; Tongyun Liu; Melissa F Kramer; Arthur L Burnett Journal: Mol Pharmacol Date: 2005-04-25 Impact factor: 4.436
Authors: Kirkwood A Pritchard; Jingsong Ou; Zhijun Ou; Yang Shi; James P Franciosi; Paul Signorino; Sushma Kaul; Cathleen Ackland-Berglund; Karin Witte; Sandra Holzhauer; Narla Mohandas; Karen S Guice; Keith T Oldham; Cheryl A Hillery Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-09-12 Impact factor: 5.464
Authors: Trinity J Bivalacqua; Biljana Musicki; Lewis L Hsu; Dan E Berkowitz; Hunter C Champion; Arthur L Burnett Journal: PLoS One Date: 2013-07-02 Impact factor: 3.240
Authors: S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze Journal: Int J Impot Res Date: 2022-08-08 Impact factor: 2.408
Authors: Biljana Musicki; Serkan Karakus; Justin D La Favor; Haolin Chen; Fabio H Silva; Mikael Sturny; Barry R Zirkin; Arthur L Burnett Journal: J Cell Physiol Date: 2020-09-24 Impact factor: 6.384